Program
casdatifan
Also written as “Casdatifan” and “AB521”.
Its studies are mostly in Carcinoma, Renal Cell · Clear-cell metastatic renal cell carcinoma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arcus Biosciences | 73 open or running | phase 3since Jun 2, 2025 | Nov 2, 2021 | May 2027phase 1 · NCT07751250 |
| AstraZeneca | 11 open or running | phase 1since May 23, 2025 | May 23, 2025 | Jan 29, 2027phase 1 · NCT07000149 |
| Exelixis | 10 open or running | phase 1since Dec 19, 2023 | Dec 19, 2023 | none ahead |
Also a collaborator on its studies: summit-therapeutics, LG Chem and Otsuka.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 2021First study: phase 1 study in Healthy ParticipantsNew to Arcus BiosciencesArcus Biosciences · NCT05117554 · 70 enrolled · Netherlands
- Sep 7, 2022Phase 1 study in Carcinoma, Renal CellArcus Biosciences · NCT05536141 · 512 planned · United States, Australia, South Korea and more
- Aug 14, 2023Phase 1 study in Healthy ParticipantsArcus Biosciences · NCT05999513 · 24 enrolled · United States
- Dec 19, 2023Exelixis's first study: phase 1 study in Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid TumorsNew to ExelixisExelixis · NCT06191796 · 25 enrolled · United States
- Mar 27, 2025Phase 1 study in Healthy ParticipantsArcus Biosciences · NCT06919991 · 14 enrolled · United States
- May 23, 2025AstraZeneca's first study: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12New to AstraZenecaAstraZeneca · NCT07000149 · 9 enrolled · Australia, South Korea
- Jun 2, 2025Phase 3 study in Clear-cell metastatic renal cell carcinomaArcus Biosciences · NCT07011719 · 720 planned · United States, Argentina, Australia and more
- Jun 8, 2026Phase 1 study in Healthy ParticipantsArcus Biosciences · NCT07641881 · 24 enrolled · United States
- Aug 3, 2026Phase 1 study in Healthy ParticipantsArcus Biosciences · NCT07751250 · 16 planned · United States
Ahead
- Jan 29, 2027Primary completion: phase 1 study in Diabetes Mellitus, Insulin-Dependent, 12AstraZeneca · NCT07000149
- May 2027Primary completion: phase 1 study in Healthy ParticipantsArcus Biosciences · NCT07751250
- Apr 2028Primary completion: phase 3 study in Clear-cell metastatic renal cell carcinomaArcus Biosciences · NCT07011719
- Mar 2029Primary completion: phase 1 study in Carcinoma, Renal CellArcus Biosciences · NCT05536141
TargetBeta
“This is a single-institution, pilot study of oral casdatifan, a selective HIF-2α inhibitor, in patients with metastatic clear cell renal cell carcinoma refractory to prior IO- and VEGF-based therapies.”study text, by rule · the study
Other programs on EPAS1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| belzutifanrule | Merck | phase 3 | 24 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07751250Healthy Participants · United States | 1 | Recruiting | Arcus Biosciences | May 2027 | 16 |
| NCT07641881Healthy Participants · United States | 1 | Completed | Arcus Biosciences | Jul 3, 2026 | 24 |
| NCT07011719Clear-cell metastatic renal cell carcinoma · United States, Argentina, Australia and more | 3 | Recruiting | Arcus Biosciences | Apr 2028 | 720 |
| NCT07000149Diabetes Mellitus, Insulin-Dependent, 12 · Australia, South Korea | 1 | Active, not recruiting | AstraZeneca | Jan 29, 2027 | 9 |
| NCT06919991Healthy Participants · United States | 1 | Completed | Arcus Biosciences | Oct 18, 2025 | 14 |
| NCT06191796Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors · United States | 1 | Terminated | Exelixis | May 12, 2025 | 25 |
| NCT05999513Healthy Participants · United States | 1 | Completed | Arcus Biosciences | Oct 31, 2023 | 24 |
| NCT05536141Carcinoma, Renal Cell · United States, Australia, South Korea and more | 1 | Recruiting | Arcus Biosciences | Mar 2029 | 512 |
| NCT05117554Healthy Participants · Netherlands | 1 | Completed | Arcus Biosciences | Feb 17, 2023 | 70 |
How it is read
Names in the registry
- “Casdatifan”, 6 entries
- “casdatifan”, 2 entries
- “AB521”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 3 studies
- Clear-cell metastatic renal cell carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.